LAV
Venture capitalActively deployingHong Kong · Seed–Series C · 3 people tracked
Also known as LAV ADVANCED MANAGEMENT COMPANY LIMITED · LAV Biosciences · LAV Brassicanapus · LAV GLOBAL MANAGEMENT COMPANY LIMITED · LAV INVESTMENT ADVISER LIMITED · LAV MANAGEMENT COMPANY, LIMITED
Investment thesis
LAV is a biomedical-focused venture capital firm that positions itself as a long-term partner to exceptional entrepreneurs building companies with breakthrough health products. The firm emphasizes domain expertise, global resources, and patient long-term capital. Its investment scope covers biopharmaceuticals, human therapeutics, medical devices, and diagnostics. LAV describes itself as a long-term thinker that bets on people, products, and quality science, aiming to be a trusted partner offering smart capital to help build great companies.
Source: firm website, verified Aug 3, 2026.
Team · 3 people
from public directoriesWhat they invest in
from 17 of 77 portfolio companiesBiotech ×16Medical Devices ×6Healthtech ×4Hardware ×2AI & Machine Learning ×1Deep Tech ×1Digital Health ×1
HQs:United States×16China×2Germany×1
Investments · 77 tracked
founders shown can be your intro pathClinical-stage biopharmaceutical company focused on identifying, developing and commercializing differentiated medicines for cancer patients.
BiotechMedical DevicesNewtown Square, US
Brent Rice(Chief Commercial Officer)Jason Zhang(Director)Cong Xu(Director)Zhengbin (Bing) Yao(Executive Officer, Director)Stuart Lutzker(Director)
BiotechSomerset, US
Fangliang Zhang, Ph.D.(Director)Yuan Xu, Ph.D.(Executive Officer, Director)Ying Huang, Ph.D.(Executive Officer)Ye Wang, M.S.(Director)
Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.
BiotechBeltsville, US
Timothy Mayer(Executive Officer)Michael Richman(Executive Officer, Director)Elaine V. Jones(Director)Udayan Guha(Executive Officer)Anne Borgman(Director)Steven P. Cobourn(Executive Officer)
San Diego, US
Board seatJudith Li· per SEC Form D · $200M raise · filed Aug 2023
San Diego, US
Board seatJudith Li· per SEC Form D · $75M raise · filed Sep 2025
BiotechSan Diego, US
RONALD MOSS(Executive Officer)ALLEN CHAO(Director)MICHAEL CHANG(Director)MARK ATTEBURY(Executive Officer)MIKAEL HAVLUCIYAN(Executive Officer)NANCY CHANG(Director)
Glaukos develops surgical and pharmaceutical therapies for ophthalmic diseases including glaucoma, corneal health, and retinal disease.
BiotechHealthtechMedical DevicesWaltham, US
Jason Hong(Director)David F. Muller(Executive Officer, Director)Jeff Dykan(Director)Anthony Natale(Director)Robert Palmisano(Director)Philip J. Ferneau(Director)
Cullinan Therapeutics develops clinical-stage T cell engager therapies targeting autoimmune diseases and cancer, leveraging immune modulation expertise to advance high-impact therapeutic candidates.
BiotechDigital Health
Inhibrx Biosciences, Inc. is a biotechnology company that was spun off as a subsidiary of Inhibrx, Inc. through a pro rata distribution of shares to shareholders.
BiotechLa Jolla, US
Mark Lappe(Executive Officer, Director)Doug Forsyth(Director)Brendan Eckelman(Director)Judith Li(Director)Jon Faiz Kayyem(Director)Margery Fischbein(Director)
KSQ Therapeutics develops eTIL therapies—engineered tumor-infiltrating lymphocyte treatments for solid tumors—using its proprietary CRISPRomics platform to identify and target novel therapeutic candidates through genome-wide CRISPR/Cas9 functional genomic screens.
AI & Machine LearningBiotechMedical DevicesCambridge, US
GEORGE GOLUMBESKI(Director)RICHARD A. MOSCICKI, PH.D.(Director)ALAN L. CRANE(Director)JAMES GILBERT(Director)JOHN TRZUPEK, PH.D.(TREASURER, SECRETARY & CHIEF FINANCIAL OFFICER)DAVID P. MEEKER, M.D.(PRESIDENT AND CHIEF EXECUTIVE OFFICER)
BiotechSan Diego, US
Kristina Burow(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)Richard Heyman(Director)Amir Nashat(Director)Robert Adelman(Director)
Milliin (迈淩) develops hemodialysis equipment and related products, including dialysis machines, dialysis water treatment systems, centralized concentrate supply systems, and dialysis dry powder.
HardwareHealthtechMedical Devices
NiKang Therapeutics is a clinical-stage biotech company developing small molecule drugs for cancer treatment, focusing on HIF2α, CDK2, and KRAS targets using structure-based drug design.
Biotech
BiotechCampbell, US
Amr Salahieh(Executive Officer, Director)Casey Gordon(Director)Mariam Maghribi(Executive Officer)
San Francisco, US
Chau Khuong(Director)Sevgi Gurkan(Executive Officer, Director, Promoter)
BoardChristy Shaffer(Director)
Readcoor develops in situ spatial profiling technology using padlock probe rolling circle amplification chemistry to detect and map RNA transcripts across tissue sections.
BiotechDeep TechHardwareHealthtechCambridge, US
Yuh-Geng Tsay(Director)Thomas Grogan(Director)Victor Tong(Director)Richard Terry(Executive Officer, Director)Evan Daugharthy(Cofounder)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Fund performance · per public LP disclosures · 2
as of Jun 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| LAV Opportunities FundLPs: The Regents of the University of California | 2020 | — | 3.4% | 1.10x | 0.17x |
| LAV VILPs: The Regents of the University of California | 2020 | — | 9.8% | 1.26x | 0.35x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Frequently asked questions
- What stage does LAV invest at?
- LAV invests at the Seed, Series A, Series B, Series C stages.
- What is LAV's typical check size?
- LAV typically writes checks of $5M – $15M.
- What sectors does LAV focus on?
- LAV focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is LAV located?
- LAV is headquartered in Hong Kong, HK.
Images
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests from seed to growth stages across artificial intelligence, health, and sustainability-focused technologies.
B Capital Group is a global venture capital firm that backs founders from early to late stage, with dedicated stage-based funds and a portfolio spanning technology, healthcare, and energy and resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
Capricorn Venture Partners is a European investment firm managing several thematic funds across growth capital, healthcare, and cleantech, as well as a combined private/quoted investment vehicle.
DCVC (Data Collective) is a venture capital firm that backs founders building companies which apply technology to major challenges across areas such as energy, biotech, agriculture, and machine learning.